Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Amicus Therapeutics, Inc. (FOLD) has a Wall Street consensus price target of $14.33, based on estimates from 24 covering analysts. With the stock currently trading at $14.37, this represents a potential downside of -0.3%. The company has a market capitalization of $4.43B.
Analyst price targets range from a low of $14.00 to a high of $14.50, representing a 3% spread in expectations. The median target of $14.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 16 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, FOLD trades at a trailing P/E of -79.8x and forward P/E of 47.4x. Analysts expect EPS to grow +768.7% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how FOLD stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonWall Street's consensus price target for FOLD is $14.33, -0.3% from its current price of $14.37. The below-market target from 24 analysts suggests limited near-term appreciation.
FOLD has a consensus rating of "Buy" based on 24 Wall Street analysts. The rating breakdown is predominantly bullish, with 16 Buy/Strong Buy ratings. The consensus 12-month price target of $14.33 implies -0.3% downside from current levels.
At a forward P/E of 47.4414x, FOLD trades at a premium valuation. The consensus price target of $14.33 (-0.3% downside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $14.5 for FOLD, while the most conservative target is $14. The consensus of $14.33 represents the median expectation. These targets typically reflect 12-month expectations.
FOLD is well covered by analysts, with 24 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 7 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FOLD stock forecast based on 24 Wall Street analysts shows a consensus price target of $14.33, with estimates ranging from $14 (bear case) to $14.5 (bull case). The median consensus rating is "Buy".
FOLD trades at a forward P/E ratio of 47.4x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on FOLD, with 1 Sell ratings and a price target of $14.33 (-0.3% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FOLD analyst price targets range from $14 to $14.5, a 3% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $14.33 consensus represents the middle ground.